UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2026

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: 001-40522

Monte Rosa Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**84-3766197**
(State or other jurisdiction of incorporation or organization)	**(I.R.S. Employer Identification No.)**
321 Harrison Avenue, Suite 900 Boston, Massachusetts	**02118**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (617) 949-2643

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	GLUE	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2026, the registrant had 85,450,119 shares of common stock, $0.0001 per share, outstanding.

Special note regarding forward-looking statements

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:

- the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our current and future research and development programs and preclinical studies, including our expectations for our molecular glue degraders, or MGDs, molecules, including our GSPT1-directed MGD MRT-2359, our out-licensed VAV1-directed MGD MRT-6160, our NEK7-directed MGDs, including MRT-8102, and our CDK2 and CCNE1 MGDs;
- the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our current and any future clinical trials, including our clinical trials for our GSPT1-directed MGD MRT-2359, our NEK7 directed MGD MRT-8102, and for our out-licensed VAV1 directed MGD MRT-6160, including statements regarding the nature of or the timing for when any results of any clinical trials will become available;
- our ability to continue to develop our proprietary discovery engine, called QuEEN™, and to expand our proteomics and translational medicine capabilities;
- the potential advantages of our discovery engine technology and product candidates;
- the extent to which our scientific approach and discovery engine technology may target proteins that have been considered undruggable or inadequately drugged;
- our plans to submit Investigational New Drug, or IND applications to the U.S. Food and Drug Administration, or the FDA for current and future product candidates;
- the potential benefits of strategic collaborations and our ability to enter into strategic collaborations with third parties who have the expertise to enable us to further develop our biological targets, product candidates and discovery engine technologies, including our agreements with Novartis AG, or Novartis, for MRT-6160 and other discovery programs and our agreement with F. Hoffmann-La Roche Ltd., or Roche Basel, and Hoffmann-La Roche Inc., or Roche US, and together with Roche Basel, collectively referred to herein as Roche;
- our ability to obtain and maintain regulatory approval of our product candidates;
- our ability to maintain and expand, including through third-party vendors, our library of MGDs;
- our ability to manufacture, including through third-party manufacturers, our product candidates for preclinical use, future clinical trials and commercial use, if approved;
- our ability to commercialize our product candidates, including our ability to establish sales, marketing and distribution capabilities for our product candidates;
- the rate and degree of market acceptance of our product candidates;
- the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
- our ability to establish and maintain intellectual property rights covering our current and future product candidates and technologies;
- the implementation of our business model and strategic plans for our business, product candidates, and technology;
- estimates of our future expenses, revenues, capital requirements, and our needs for additional capital;
- our expected use of proceeds from sales of our common stock in "at-the-market" offerings and other offerings, and the period over which such proceeds, together with existing cash, will be sufficient to meet our operating needs;
- our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;
- our financial performance;

- developments in laws and regulations in the United States, or the U.S., and foreign countries;
- the success of competing therapies that are or may become available;
- our ability to attract and retain key scientific or management personnel;
- the effect of global economic uncertainty and financial market volatility caused by economic effects of rising inflation and interest rates, global health crises, geopolitical events, elections, changes in international trade relationships and military conflicts on any of the foregoing or other aspects of our business or operations;
- the effect of any geopolitical conflicts or new or increased international tariffs, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies, ongoing clinical trials and future clinical trials; and
- other risks and uncertainties, including those listed under the section entitled “Risk factors" and those included in "Part I, Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, or our 2025 Annual Report, filed with the Securities and Exchange Commission, or the SEC, on March 17, 2026.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

TRADEMARKS

Solely for convenience, our trademarks and trade names in this report are sometimes referred to without the ® and ™ symbols, but such references should not be construed as any indicator that we will not assert, to the fullest extent under applicable law, our rights thereto.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets (Unaudited)	1
	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)	2
	Condensed Consolidated Statements of Stockholders' Equity (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows (Unaudited)	5
	Notes to the Condensed Consolidated Financial Statements (Unaudited)	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	32
PART II.	OTHER INFORMATION	33
Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	35
Item 3.	Defaults Upon Senior Securities	35
Item 4.	Mine Safety Disclosures	35
Item 5.	Other Information	35
Item 6.	Exhibits	36
Signatures		37

Part I — Financial Information

Item 1. Financial Statements

Monte Rosa Therapeutics, Inc.
Condensed consolidated balance sheets (unaudited)

(in thousands, except share and per share amounts)	September 30, 2026	December 31, 2025
Assets		
Current assets:		
Cash and cash equivalents	$ 45,180	$ 129,883
Marketable securities	532,546	247,221
Collaboration receivable	50,000	7,000
Other receivables	7,624	4,600
Prepaid expenses and other current assets	4,715	4,481
Total current assets	640,065	393,185
Property and equipment, net	28,632	25,986
Operating lease right-of-use assets	23,343	24,386
Restricted cash	4,918	4,954
Other long-term assets	767	148
Total assets	$ 697,725	$ 448,659
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	$ 3,347	$ 3,550
Accrued expenses and other current liabilities	33,414	26,694
Current deferred revenue	21,098	29,571
Current portion of operating lease liability	4,187	4,397
Total current liabilities	62,046	64,212
Deferred revenue, net of current	102,261	111,332
Defined benefit plan liability	5,131	5,265
Operating lease liability, net of current	32,079	34,794
Total liabilities	201,517	215,603
Commitments and contingencies (Note 8)		
Stockholders' equity		
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	—	—
Common stock, $0.0001 par value; 500,000,000 shares authorized, 85,431,211 and 65,543,723 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	9	7
Additional paid-in capital	1,064,442	714,090
Accumulated other comprehensive loss	(6,192)	(3,827)
Accumulated deficit	(562,051)	(477,214)
Total stockholders' equity	496,208	233,056
Total liabilities and stockholders' equity	$ 697,725	$ 448,659

See accompanying notes to the condensed consolidated financial statements.

Monte Rosa Therapeutics, Inc.
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)

(in thousands, except share and per share amounts)	Three months ended September 30, 2026	Three months ended September 30, 2025	Nine months ended September 30, 2026	Nine months ended September 30, 2025
Collaboration revenue	$ 54,366	$ 12,768	$ 67,544	$ 120,891
Operating expenses:				
Research and development	45,363	36,678	137,396	99,521
General and administrative	10,942	9,065	31,251	25,863
Total operating expenses	56,305	45,743	168,647	125,384
Loss from operations	(1,939)	(32,975)	(101,103)	(4,493)
Other income:				
Interest income	5,625	2,746	17,132	9,253
Foreign currency exchange gain (loss)	93	(29)	110	1,534
Gain on disposal of property and equipment	—	—	—	59
Total other income	5,718	2,717	17,242	10,846
Net income (loss) before income taxes	3,779	(30,258)	(83,861)	6,353
Income tax (provision) benefit	(716)	3,177	(976)	1,156
Net income (loss)	$ 3,063	$ (27,081)	$ (84,837)	$ 7,509
Comprehensive income (loss):				
Provision for pension benefit obligation	52	53	161	154
Unrealized (loss) gain on available-for-sale securities	(1,079)	73	(2,526)	(45)
Comprehensive income (loss)	$ 2,036	$ (26,955)	$ (87,202)	$ 7,618
Earnings (loss) per share:				
Basic	$ 0.03	$ (0.33)	$ (0.84)	$ 0.09
Diluted	$ 0.03	$ (0.33)	$ (0.84)	$ 0.09
Weighted average number of shares outstanding:				
Basic	101,793,104	82,397,753	101,058,958	82,245,324
Diluted	108,615,714	82,397,753	101,058,958	82,942,723

See accompanying notes to the condensed consolidated financial statements.

Monte Rosa Therapeutics, Inc.
Condensed consolidated statements of stockholders' equity (unaudited)

(in thousands, except share amounts)	Common stock Shares	Common stock Amount	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total Stockholders' equity
Balance—January 1, 2026	65,543,723	$ 7	714,090	$ (3,827)	$ (477,214)	$ 233,056
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance cost of $21,187	13,000,000	1	323,810	—	—	323,811
Exercise of pre-funded warrants	5,016,628	—	—	—	—	—
Restricted common stock vesting	186,515	—	—	—	—	—
Exercise of common stock options	574,839	—	4,522	—	—	4,522
Provision for pension benefit obligation	—	—	—	55	—	55
Stock-based compensation expense	—	—	5,949	—	—	5,949
Unrealized loss on available-for-sale securities	—	—	—	(974)	—	(974)
Net loss	—	—	—	—	(44,503)	(44,503)
Balance—March 31, 2026	84,321,705	$ 8	$ 1,048,371	$ (4,746)	$ (521,717)	$ 521,916
Exercise of pre-funded warrants	509,300	1	(1)	—	—	—
Restricted common stock vesting	1,749	—	—	—	—	—
Exercise of common stock options	346,713	—	2,600	—	—	2,600
Provision for pension benefit obligation	—	—	—	54	—	54
Stock-based compensation expense	—	—	5,970	—	—	5,970
Unrealized loss on available-for-sale securities	—	—	—	(473)	—	(473)
Issuance of shares under employee stock purchase plan	46,960	—	611	—	—	611
Net loss	—	—	—	—	(43,397)	(43,397)
Balance—June 30, 2026	85,226,427	$ 9	$ 1,057,551	$ (5,165)	$ (565,114)	$ 487,281
Exercise of pre-funded warrants	115,692	—	—	—	—	—
Restricted common stock vesting	2,124	—	—	—	—	—
Exercise of common stock options	86,968	—	568	—	—	568
Provision for pension benefit obligation	—	—	—	52	—	52
Stock-based compensation expense	—	—	6,323	—	—	6,323
Unrealized loss on available-for-sale securities	—	—	—	(1,079)	—	(1,079)
Net income	—	—	—	—	3,063	3,063
Balance—September 30, 2026	85,431,211	$ 9	$ 1,064,442	$ (6,192)	$ (562,051)	$ 496,208

See accompanying notes to the condensed consolidated financial statements.

Monte Rosa Therapeutics, Inc.
Condensed consolidated statements of stockholders' equity (unaudited) - continued

(in thousands, except share amounts)	Common stock Shares	Common stock Amount	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total Stockholders' equity
Balance—January 1, 2025	61,507,446	$ 6	664,874	$ (3,356)	$ (438,588)	$ 222,936
Exercise of common stock options	2,375	—	14	—	—	14
Provision for pension benefit obligation	—	—	—	48	—	48
Stock-based compensation expense	—	—	5,298	—	—	5,298
Unrealized loss on available-for-sale securities	—	—	—	(21)	—	(21)
Net income	—	—	—	—	46,885	46,885
Balance—March 31, 2025	61,509,821	$ 6	$ 670,186	$ (3,329)	$ (391,703)	$ 275,160
Restricted common stock vesting	112,159	—	—	—	—	—
Provision for pension benefit obligation	—	—	—	53	—	53
Stock-based compensation expense	—	—	4,894	—	—	4,894
Unrealized loss on available-for-sale securities	—	—	—	(97)	—	(97)
Issuance of shares under employee stock purchase plan	95,369	—	365	—	—	365
Net loss	—	—	—	—	(12,295)	(12,295)
Balance—June 30, 2025	61,717,349	$ 6	$ 675,445	$ (3,373)	$ (403,998)	$ 268,080
Exercise of common stock options	72,890	—	348	—	—	348
Provision for pension benefit obligation	—	—	—	53	—	53
Stock-based compensation expense	—	—	4,364	—	—	4,364
Unrealized loss on available-for-sale securities	—	—	—	73	—	73
Net loss	—	—	—	—	(27,081)	(27,081)
Balance—September 30, 2025	61,790,239	$ 6	$ 680,157	$ (3,247)	$ (431,079)	$ 245,837

See accompanying notes to the condensed consolidated financial statements.

Monte Rosa Therapeutics, Inc.
Condensed consolidated statements of cash flows (unaudited)

(in thousands)	Nine months ended September 30, 2026	2025
Cash flows from operating activities:		
Net (loss) income	$ (84,837)	$ 7,509
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities		
Stock-based compensation expense	18,242	14,556
Depreciation	6,087	6,268
Net accretion of discounts/premiums on marketable securities	(1,608)	(2,232)
Gain on disposal of property and equipment	—	(59)
Changes in operating assets and liabilities		
Collaboration receivable	(43,000)	—
Other receivables	(3,024)	(4,792)
Prepaid expenses and other assets	(853)	(772)
Accounts payable	(519)	(3,096)
Accrued expenses and other current liabilities	6,451	(883)
Defined benefit plan liability	26	1,192
Right-of-use assets and operating lease liabilities	(1,882)	(781)
Deferred revenue	(17,544)	3,306
Net cash (used in) provided by operating activities	$ (122,461)	$ 20,216
Cash flows from investing activities:		
Purchases of property and equipment	(8,149)	(3,933)
Purchases of marketable securities	(499,777)	(223,016)
Proceeds from maturities of marketable securities	213,534	190,182
Net cash used in investing activities	$ (294,392)	$ (36,767)
Cash flows from financing activities:		
Proceeds from exercise of employee stock options	7,690	362
Proceeds from underwritten public offering, net of underwriter's commission of $20,700	324,300	—
Payment of offering costs	(487)	—
Proceeds from employee stock purchase plan	611	365
Net cash provided by financing activities	$ 332,114	$ 727
Net decrease in cash, cash equivalents and restricted cash	$ (84,739)	$ (15,824)
Cash, cash equivalents and restricted cash—beginning of period	134,837	229,117
Cash, cash equivalents and restricted cash—end of period	$ 50,098	$ 213,293
Reconciliation of cash, cash equivalents and restricted cash		
Cash and cash equivalents	$ 45,180	$ 208,343
Restricted cash	4,918	4,950
Total cash, cash equivalents and restricted cash	$ 50,098	$ 213,293
Supplemental disclosure of noncash items		
Purchases of property and equipment in accounts payable and accrued expenses	$ 734	$ 439

See accompanying notes to the condensed consolidated financial statements.

Monte Rosa Therapeutics, Inc.
Notes to the condensed consolidated financial statements
(unaudited)

1. Description of business and liquidity

Business

Monte Rosa Therapeutics, Inc. is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically-relevant proteins. As used in these condensed consolidated financial statements, unless the context otherwise requires, references to the Company or Monte Rosa refer to Monte Rosa Therapeutics, Inc. and its wholly owned subsidiaries Monte Rosa Therapeutics AG and Monte Rosa Therapeutics Securities Corporation. Monte Rosa Therapeutics AG, a Swiss operating company, was incorporated under the laws of Switzerland in April 2018. Monte Rosa Therapeutics, Inc. was incorporated in Delaware in November 2019. The Company is headquartered in Boston, Massachusetts with research operations in both Boston and Basel, Switzerland.

Liquidity considerations

Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and raising capital and has financed its operations primarily through issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of common stock or warrants to purchase common stock, registered direct offerings, and through its collaborations with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., or Roche, and with Novartis AG, or Novartis.

The Company's continued discovery and development of its product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

As of September 30, 2026, the Company had an accumulated deficit of $562.1 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $84.8 million for the nine months ended September 30, 2026 and $38.6 million for the year ended December 31, 2025. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash, cash equivalents, and marketable securities of $577.7 million as of September 30, 2026 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the third quarter interim condensed consolidated financial statements are issued. However, additional funding will be necessary to fund future discovery research, preclinical and clinical activities. The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although it has been successful in raising capital in the past, there is no assurance that the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and the Company may not be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect the Company's business prospects, and even the ability to continue operations.

2. Summary of significant accounting policies

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, and are stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB. All intercompany balances and transactions have been eliminated in consolidation.

Unaudited financial information

The Company's condensed consolidated financial statements included herein have been prepared in conformity with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. In the Company's opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The

Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Recently issued accounting pronouncements

The Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the Jumpstart Our Business Startups Act, or the JOBS Act.

In November 2024, the FASB issued ASU 2024-03, *Income Statement Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)*, which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 requires disclosure of, in a tabular presentation, each relevant expense caption on the face of the income statement that includes any of the following natural expenses: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depreciation, depletion, and amortization (DD&A) recognized as part of oil- and gas-producing activities or other types of depletion expenses. The tabular disclosure would also include certain other expenses, when applicable. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

3. Fair value measurements

The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):

	As of September 30, 2026			
	Level 1	Level 2	Level 3	Total
Current assets				
Money market funds	$ 44,582	$ —	$ —	$ 44,582
Pension plan assets	—	12,306	—	12,306
Corporate debt securities	—	269,551	—	269,551
U.S. Treasury securities	—	262,995	—	262,995
Total assets measured at fair value	$ 44,582	$ 544,852	$ —	$ 589,434

	As of December 31, 2025			
	Level 1	Level 2	Level 3	Total
Current assets				
Money market funds	$ 129,279	$ —	$ —	$ 129,279
Pension plan assets	—	12,440	—	12,440
Corporate debt securities	—	99,596	—	99,596
U.S. Treasury securities	—	147,625	—	147,625
Total assets measured at fair value	$ 129,279	$ 259,661	$ —	$ 388,940

Money market funds are highly liquid investments and are actively traded. The pricing information on the Company's money market funds is based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured members held within the Columna Collective Foundation Group investment fund and is classified within Level 2 of the fair value hierarchy.

Marketable securities consist of corporate debt securities and U.S. Treasury securities which are classified as available-for-sale pursuant to ASC 320, *Investments—Debt and Equity Securities*. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities based on historical data and other observable inputs.

There were no transfers among Level 1, Level 2 or Level 3 categories in the nine months ended September 30, 2026 and 2025.

4. Marketable securities

Marketable securities as of September 30, 2026 consisted of the following (in thousands):

Description	Amortized cost	Unrealized gains	Unrealized losses	Fair value
Corporate debt securities	$ 270,931	$ 9	$ (1,389)	$ 269,551
U.S. Treasury securities	263,977	—	(982)	262,995
Total	$ 534,908	$ 9	$ (2,371)	$ 532,546

Marketable securities as of December 31, 2025 consisted of the following (in thousands):

Description	Amortized cost	Unrealized gains	Unrealized losses	Fair value
Corporate debt securities	$ 99,543	$ 53	$ —	$ 99,596
U.S. Treasury securities	147,514	111	—	147,625
Total	$ 247,057	$ 164	$ —	$ 247,221

As of September 30, 2026, unrealized gain and losses on marketable securities are recorded in accumulated other comprehensive loss in equity on the accompanying condensed consolidated balance sheet. The aggregate fair value of securities in a loss position was $514.4 million and $3.2 million as of September 30, 2026 and December 31, 2025, respectively. There were no realized gains or losses recognized on the sale or maturity of marketable securities for the three and nine months ended September 30, 2026 and 2025 and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive loss for the same periods.

The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The Company also believes that it will be able to collect both principal and interest amounts due to it at maturity.

5. Property and equipment, net

Property and equipment, net, consist of the following (in thousands):

	September 30, 2026	December 31, 2025
Laboratory equipment	$ 33,394	$ 27,022
Computer hardware and software	1,388	1,388
Furniture and fixtures	1,530	1,402
Leasehold improvements	25,687	23,669
Construction in process	326	118
Total property and equipment, at cost	$ 62,325	$ 53,599
Less: accumulated depreciation	(33,693)	(27,613)
Property and equipment, net	$ 28,632	$ 25,986

The following table summarizes depreciation expense incurred (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Depreciation expense	$ 2,144	$ 2,095	$ 6,087	$ 6,268

6. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	September 30, 2026	December 31, 2025
Accrued compensation and benefits	$ 9,334	$ 9,998
Accrued research and development	18,793	15,118
Accrued fixed asset purchase	326	57
Accrued value added tax	3,022	—
Other	1,939	1,521
Total accrued expenses and other current liabilities	$ 33,414	$ 26,694

7. Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use, or ROU, assets and operating lease liabilities in the condensed consolidated balance sheets. The Company has no finance leases as of September 30, 2026.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit rate, management estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

Klybeckstrasse Lease

In March 2021, the Company entered into an operating lease agreement, or the Klybeckstrasse Lease, for office and laboratory space with Wincasa AG, or the Basel Landlord, that occupies approximately 21,422 square feet located at Klybeckstrasse 191, 4057 Basel, Basel-City, Switzerland. In April 2023, the Company and the Basel Landlord amended the Klybeckstrasse Lease which increased the office and laboratory space square footage from 21,422 square feet to 44,685 square feet and extended the term of the lease through June 30, 2027. In March 2026, the Company and the Basel Landlord again amended the Klybeckstrasse Lease, the Second Amendment, to extend the term of the lease through June 30, 2028. The Second Amendment was accounted for as a lease modification and resulted in increases to the related ROU asset and operating lease liability of $1.0 million.

Harrison Avenue Lease

In December 2021, the Company entered into a non-cancelable lease agreement, or the Harrison Avenue Lease, for 63,327 square feet of office and laboratory space to support its expanding operations. The term of the lease commenced on April 1, 2022 and the Company's obligation to pay rent began on December 21, 2022. The initial term of the lease is through November 30, 2032, at which point the Company has the option to extend the lease an additional 5 years. The Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The annual base rent under the Harrison Avenue Lease is $95 per square foot for the first year, which is subject to scheduled annual increases of 3%, plus certain costs, operating expenses and property management fees.

The components of lease expense are as follows (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Operating lease expense	$ 1,661	$ 1,654	$ 4,953	$ 4,910
Variable lease expense	769	745	2,171	1,877
Total lease expense	$ 2,430	$ 2,399	$ 7,124	$ 6,787

The variable lease expenses generally include common area maintenance and property taxes.

The following table summarizes lease expense incurred (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Research and development	$ 2,091	$ 2,028	$ 6,308	$ 5,714
General and administrative	339	371	816	1,073
Total lease expense	$ 2,430	$ 2,399	$ 7,124	$ 6,787

Short-term lease costs for the three and nine months ended September 30, 2026 and 2025 were immaterial.

The weighted average remaining lease term and discount rate related to the Company's leases are as follows:

	September 30, 2026	December 31, 2025
Weighted average remaining lease term (years)	6.0	6.8
Weighted average discount rate	9.8%	9.9%

Supplemental cash flow information and other information relating to the Company's leases are as follows (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Cash paid for amounts included in the measurement of lease liabilities	$ 2,565	$ 963	$ 6,558	$ 2,818
Amortization of ROU assets	$ 715	$ 637	$ 2,066	$ 1,827

Future minimum lease payments under non-cancelable leases as of September 30, 2026 for each of the years ending December 31 are as follows (in thousands):

Undiscounted lease payments	
Remainder of 2026	$ 1,410
2027	8,174
2028	7,879
2029	7,575
2030	7,802
Thereafter	15,624
Total undiscounted minimum lease payments	48,464
Less: Imputed interest	(12,198)
Total operating lease liability	$ 36,266

8. Commitments and contingencies

Legal proceedings

From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. As of September 30, 2026, the Company is not a party to any litigation and does not have a contingency reserve established for any litigation liabilities.

9. Collaboration and license agreements

Roche collaboration and license agreement

Description

In October 2023, Monte Rosa Therapeutics AG, a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc, or the Company, entered into a collaboration and license agreement, or the Roche Agreement, with Roche. Pursuant to the Roche Agreement, the parties will seek to identify and develop molecular glue degraders, or MGDs, against cancer or neurological disease targets using the Company’s proprietary drug discovery engine for an initial set of targets in oncology and neuroscience selected by Roche, wherein a certain number of targets selected by Roche are for a limited time subject to replacement rights owned by Roche. The Company will lead preclinical discovery and research activities with Roche leading late preclinical and clinical development activities.

Under the Roche Agreement, Roche will have a worldwide, exclusive license under patents and know-how controlled by the Company to develop and commercialize products directed to applicable targets. The license exclusivity is subject to the Company’s retained rights solely to fulfill its obligations under the arrangement.

The research collaboration activities governed by the Roche Agreement are overseen by a joint research committee.

Unless earlier terminated, the Roche Agreement will remain in effect for each product licensed under the Roche Agreement until expiration of the royalty term for the applicable product. The parties have included termination provisions in the Roche Agreement, allowing termination of the Roche Agreement in its entirety, on a country-by-country or a target-by-target basis.

Pricing

In November 2023, the Company received a $50.0 million non-refundable upfront payment for the initial set of targets. Pursuant to the terms of the Roche Agreement, the Company expects to be entitled to receive from Roche certain variable consideration including potential preclinical milestones up to $172 million, and potential clinical, commercial and sales milestones exceeding $2 billion. The Company is also eligible to receive tiered royalties ranging from high-single-digits to low-teens on any products that are commercialized by Roche as a result of the collaboration.

To date through September 30, 2026, the Company has received $16.0 million related to Roche's decision to pay preclinical milestones and $3.0 million related to Roche's decision to exercise its option rights to replace certain targets for research and development services. The related payments are initially classified as deferred revenue in the accompanying condensed consolidated balance sheet and recognized in revenue as the related research and development services are performed.

Accounting

This agreement represents a transaction with a customer and therefore is accounted for under ASC 606, *Revenue From Contracts With Customers*.

The Company determined that the development and commercialization licenses for each of the collaboration targets is neither capable of being distinct nor distinct within the context from the promised initial research services. In addition, the Company has determined that each target in the agreement is distinct from other targets because: (i) Roche can benefit from the license and research services for a given target on their own since the results related thereto can be evaluated discretely and (ii) the results of the research and development of each target does not affect either the Company's ability to perform or Roche's ability to assess the results for any other target. As such, the Company has identified certain performance obligations within the agreement as follows:

- Performance obligations for the research and development of initial targets; and
- Performance obligations for the research and development services related to Roche's option to replace certain targets.

The total transaction price of the Roche Agreement is allocated to the performance obligations based on their relative standalone selling price. The Company developed the standalone selling price for the performance obligations included in the Roche Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The allocated transaction price is recognized as revenue from collaboration agreements in one of two ways:

- Research and development of the initial targets: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to said research and development target. The transfer of control occurs over this period and, in management's judgment, is the best measure of progress towards satisfying the performance obligation.
- Option rights to replace targets: The transaction price allocated to the replacement option rights, which are considered material rights, is deferred until the period that Roche elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target. Upon Roche's exercise of a replacement option right, the Company will recognize the portion of the transaction price allocated using the input method described above. Any payments made to exercise replacement option rights will be added to the allocated value and recognized as the related services are performed.

To date through September 30, 2026, a total of $55.8 million related to the Roche Agreement has been recognized as collaboration revenue in the condensed consolidated statements of operations and comprehensive income (loss), including $2.0 million and $9.5 million recognized in the three and nine months ended September 30, 2026, respectively. The remaining $13.2 million of the upfront payment and subsequent milestone and replacement target payments related to customer options are recorded as deferred revenue in the liabilities section of the condensed consolidated balance sheet, with $7.2 million included in current liabilities and $6.0 million included in non-current liabilities.

The following table summarizes the deferred revenue amounts allocated to the Roche Agreement performance obligations (in thousands):

	September 30, 2026	December 31, 2025
Roche Agreement performance obligations		
Research and development of initial targets	$ 6,248	$ 14,140
Research and development for replacement targets	6,914	8,517
Total Roche Agreement deferred revenue	$ 13,162	$ 22,657

The Company expects that the remaining deferred revenue for the initial targets will be recognized within 11 months. The Company expects that deferred revenue related to replacement targets will be recognized within 25 months. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations for the initial and replacement targets. Any amounts remaining in deferred revenue will be recognized at the conclusion of the Roche Agreement in October 2028.

As of September 30, 2026, potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.

2024 Novartis License Agreement

Description

In October 2024, Monte Rosa Therapeutics AG, a wholly-owned subsidiary of the Company, entered into a license agreement, the 2024 Novartis Agreement, with Novartis. Pursuant to the 2024 Novartis Agreement, the Company granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to develop, manufacture, and commercialize VAV1 MGDs, including MRT-6160, In September 2026, the Company announced that Novartis initiated a Phase 2 clinical study of MRT-6160 (DDY391) in participants with Sjögren's disease, and MRT-6160 is currently in Phase 2 clinical development for immune-mediated conditions. The Company was responsible for completing the Phase 1 clinical study and Novartis is responsible for all subsequent development and commercial activities starting at Phase 2.

Pricing

In December 2024, the Company received a $150 million non-refundable upfront payment. Pursuant to the 2024 Novartis Agreement, the Company is entitled to receive from Novartis up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies including (a) potential development and regulatory milestone payments, exceeding $1.5 billion if multiple indications achieve regulatory approval in multiple territories, and (b) potential sales milestone payments in connection with sales outside of the U.S., and tiered royalties on sales outside of the U.S. Novartis will be responsible for costs associated with Phase 2 clinical studies. The Company and Novartis also agreed to a net profit and loss sharing arrangement, pursuant to which the Company will co-fund any global clinical development from Phase 3 onwards and will share 30% of any profits and losses associated with the manufacturing and commercialization of the licensed products in the U.S. The Company has defined opportunities to opt out of the net profit and loss sharing arrangement prior to the initiation of Phase 3 clinical trials, in such case, sales in the U.S. would be entitled to the potential sales milestone payments and tiered royalties as sales outside of the U.S. Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Company and Novartis.

Accounting

The goods and services that the Company was obligated to deliver and perform (the License and Licensor Clinical Trial) were accounted for under ASC 606 as they represented a transaction with a customer.

The Company has concluded that the License and the completion of the Licensor Clinical Trial promises are treated as a single, combined performance obligation. The Company has determined the total transaction price to be $150 million, which consists solely of the upfront payment. All milestone payments were constrained as the achievement of the milestones are contingent upon the success of the underlying research and development activities and are generally outside the control of the Company. The Company’s options to share in further development and commercialization efforts via its opt-in/opt-out rights will be assessed and accounted for as separate units of accounting under the relevant guidance if, and when, such options are exercised by the Company.

The revenue the Company recognized associated with the combined performance obligation was recognized over time using a cost-based input methodology. The transfer of control occurred over the course of the Licensor Clinical Trial

promise and, in management's judgment, was the best measure of progress towards satisfying the combined performance obligation.

The total transaction price of $150 million plus $1.2 million of incremental cost reimbursements related to the 2024 Novartis Agreement was recognized as collaboration revenue in the condensed consolidated statements of operations and comprehensive income (loss) by September 30, 2025.

To date through September 30, 2026, the Company has earned $50 million in connection with achievement of a milestone associated with the first patient visit of a Novartis Phase 2 study evaluating MRT-6160 (DDY391) in participants with Sjögren's disease. As there were no remaining performance obligations related to this milestone, the $50 million to be received from Novartis was recognized as collaboration revenue in the three and nine months ended September 30, 2026 and was recorded in collaboration receivable as of September 30, 2026.

2025 Novartis License Agreement

Description

In September 2025, Monte Rosa Therapeutics AG, a wholly-owned subsidiary of the Company, entered into a collaboration, option, and license agreement, the 2025 Novartis Agreement, with Novartis. Pursuant to the 2025 Novartis Agreement, the Company granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to degraders for one immunology and inflammation, or I&I program, or the First Licensed Program, and the option to obtain exclusive, royalty-bearing, sublicensable and transferable licenses with respect to two additional programs from the Company's growing preclinical immunology portfolio, or the Options, and the programs, or the Optioned I&I Programs. Such Options are individually exercisable at Novartis's discretion until a program meets criteria for investigational new drug application-filing-readiness. On a program-by-program basis, if Novartis does not exercise an Option, all rights with respect to such program are retained by the Company; if Novartis does exercise its Option, such program becomes a Licensed Program, or together, with the First Licensed Program, the Licensed Programs. Under the 2025 Novartis Agreement, the Company will apply its proprietary AI/ML-enabled QuEEN™ engine for the discovery and development of degraders for the First Licensed Program and the Optioned I&I Programs. The Licensed Programs will be further developed and commercialized by Novartis, unless otherwise agreed to by the parties in accordance with the 2025 Novartis Agreement. Research activities for the Licensed Programs governed by the 2025 Novartis Agreement will be overseen by a Joint Research Committee.

Pricing

In September 2025, the Company received a $120.0 million non-refundable upfront payment from Novartis. Pursuant to the 2025 Novartis Agreement, the Company is entitled to receive from Novartis payments to maintain the Options totaling up to $60.0 million, and is eligible to receive from Novartis (1) preclinical milestone payments relating to the First Licensed Program and option exercise payments related to the Options of up to $180.0 million, (2) up to $5.4 billion in clinical development, regulatory, and sales milestones relating to the First Licensed Program and the two Optioned I&I Programs, beginning upon initiation of Phase 1 studies, including (a) potential development and regulatory milestone payments up to $2.2 billion if regulatory approval is achieved for multiple indications in multiple territories and (b) potential sales milestone payments up to $3.2 billion, allocated across licensed products, and (3) tiered royalties on global net sales in the high-single to low double-digit range for the First Licensed Program and in the low double-digit range for the two Optioned I&I Programs. The Company will be responsible for costs related to research activities, while Novartis will be responsible for costs related to development and commercialization activities.

Accounting

The goods and services that the Company is obligated to deliver and perform under the 2025 Novartis Agreement will be accounted for under ASC 606 as they represent a transaction with a customer.

The Company has concluded that the transaction price at inception is $180 million, which consists of the $120 million upfront payment and $60 million of option maintenance payments due over the course of the contract term. The Company has identified the following performance obligations in the contract:

- License and research services for an immunology target
- Research services for certain immunology targets to support the Immunology License Options
- Material Right First Immunology License Option
- Material Right Second Immunology License Option

The total transaction price of the 2025 Novartis Agreement is allocated to the performance obligations based on their relative standalone selling prices, or the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The standalone selling price of performance obligations related to license and research services were determined using a cost-plus margin approach. The standalone selling price related to material rights for immunology license options were determined by benchmarking to comparable transactions, probability adjusted for the likelihood of exercise.

The allocated transaction price is recognized as revenue from collaboration agreements in one of two ways:

- License and research services for immunology targets: The Company recognizes the portion of the transaction price allocated to each of the research performance obligations as the research services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to said research services. The transfer of control occurs over this period and, in management's judgment, is the best measure of progress towards satisfying the performance obligation.
- Material option rights: The transaction price allocated to the options rights, which are considered material rights, is deferred until the period that Novartis elects to exercise its option right to license and commercialize the underlying immunology program. The Company will recognize the portion of the transaction price allocated to the option rights upon exercise. The Company has no further obligations to perform research services subsequent to the option exercise.

To date through September 30, 2026, $9.8 million of revenue related to the 2025 Novartis Agreement has been recognized as collaboration revenue in the condensed consolidated statements of operations and comprehensive income (loss), including $2.3 million and $8.0 million recognized in the three and nine months ended September 30, 2026, respectively. The remaining $110.2 million has been recorded as deferred revenue on the condensed consolidated balance sheets, with $13.9 million included in current liabilities related to performance obligations expected to be completed within 12 months from September 30, 2026 and $96.3 million included in non-current liabilities related to performance obligations expected to be completed later than 12 months from September 30, 2026. The total transaction price of $180 million includes $60 million of future option maintenance payments which are not included in deferred revenue on the condensed consolidated balance sheet.

The following table summarizes the unearned amount of the 2025 Novartis Agreement transaction price allocated to the performance obligations (in thousands):

	September 30, 2026	December 31, 2025
2025 Novartis Agreement performance obligations		
License and research services for named immunology target	$ 6,255	$ 7,019
Research services to support immunology license options	78,413	85,698
Material right - first immunology license option	49,091	49,091
Material right - second immunology license option	36,439	36,439
Total unearned amount of transaction price	$ 170,198	$ 178,247

The Company expects that the remaining deferred revenue for the license and research services for a named immunology target and research services for two additional immunology targets to be recognized within 49 months. The deferred revenue related to material right license options will be recognized when Novartis exercises such options rights or at the expiration of the option rights. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations related to research services.

10. Equity

Undesignated preferred stock

The Company had 10,000,000 shares authorized of undesignated preferred stock, par value of $0.0001, of which no shares were issued and outstanding as of September 30, 2026.

Common stock

As of September 30, 2026, the Company had 500,000,000 shares of common stock authorized, of which 85,431,211 shares were issued and outstanding.

Additionally, as of September 30, 2026, the Company had 16,372,266 outstanding pre-funded warrants to purchase shares of the Company's common stock to accredited investors. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share at any time after the date of issuance. A holder of a pre-funded warrant may not exercise such pre-funded warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise.

The Company has assessed the pre-funded warrants for appropriate equity or liability classification. During this assessment, the Company determined the pre-funded warrants are a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrants are indexed to the Company's common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Based on the results of this assessment, the Company concluded that the pre-funded warrants are a freestanding equity-linked financial instrument that meets the criteria for equity classification under ASC 480 and ASC 815. Accordingly, the pre-funded warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. The Company also determined that the pre-funded warrants should be included in the determination of basic and diluted earnings per share in accordance with ASC 260, *Earnings per Share*.

The holders of common stock are entitled to dividends when and if declared by the Company's board of directors, subject to the preferences applicable to any outstanding shares of preferred stock. The Company's board of directors has not declared any dividends and the Company has not paid any dividends.

The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.

During the three and nine months ended September 30, 2026, 115,695 and 5,641,658 pre-funded warrants were exercised, respectively. These exercises included net-settlements pursuant to the terms of the applicable pre-funded warrant agreements, whereby the holders elected to have pre-funded warrants withheld in a cashless exercise in lieu of paying the $0.0001 per share exercise price. As a result, during the three months ended September 30, 2026, 3 pre-funded warrants were withheld to cover the aggregate exercise price, resulting in the issuance of 115,692 shares of common stock from the exercise of pre-funded warrants. During the nine months ended September 30, 2026, 38 pre-funded warrants were withheld to cover the aggregate exercise price, resulting in the issuance of 5,641,620 shares of common stock from the exercise of pre-funded warrants. During the three and nine months ended September 30, 2025, no pre-funded warrants were exercised.

As of September 30, 2026 and December 31, 2025, the Company has reserved the following shares of common stock for the exercise of stock options, vesting of restricted stock and pre-funded warrants:

	September 30, 2026	December 31, 2025
Options to purchase common stock	15,867,747	14,064,599
Unvested restricted common stock units	1,171,416	775,765
Pre-funded warrants	16,372,266	20,638,924
Total common stock shares reserved	33,411,429	35,479,288

At-the-market offerings

In July 2022, the Company entered into a sales agreement, or the 2022 Sales Agreement, with Jefferies LLC, or Jefferies, as amended on March 20, 2025, pursuant to which the Company could offer and sell shares of its common stock pursuant to the then-effective prospectus from time to time in "at-the-market" offerings, or the ATM Program, through Jefferies, as the Company's sales agent. Effective January 7, 2026, the Company terminated the prospectus pursuant to which it had been able to sell shares from time to time in at-the-market offerings under the 2022 Sales Agreement.

On February 11, 2026, the Company filed a registration statement on Form S-3ASR (File No. 333-293389) with the SEC, or the 2026 Automatic Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company's common stock, debt securities or other equity securities in one or more offerings. In connection with the ATM Program and pursuant to the 2026 Automatic Shelf Registration Statement, the Company filed a new prospectus supplement with the SEC on February 11, 2026, for the offer and sale of up to $100.0 million of shares of common stock from time to time through Jefferies.

The Company agreed to pay Jefferies a commission of up to 3.0% of the gross proceeds of any shares sold by Jefferies under the 2022 Sales Agreement. During the nine months ended September 30, 2026 and 2025, the Company did not sell shares of common stock under the ATM Program.

Underwritten public offerings

In January 2026, the Company entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. as representatives of the several underwriters, related to an underwritten public offering, or the 2026 Offering, of 13,000,000 shares of common stock at a price of $24.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a price of $23.9999 per pre-funded warrant, which represents the price per share at which shares of common stock were sold in the 2026 Offering, minus $0.0001, which is the exercise price of each pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the 2026 Offering were $345.0 million, or aggregate net proceeds of $323.8 million after deducting the underwriter discounts, commissions, and other offering costs.

11. Stock-based compensation

2020 Stock incentive plan

The Company's 2020 Stock Option and Grant Plan, or the 2020 Plan, provided for the Company to grant stock options, restricted stock and other stock awards, to employees, non-employee directors, and consultants. Upon the effectiveness of the 2021 Plan (as defined below), no further issuances were made under the 2020 Plan.

2021 Stock Option and Incentive Plan

The Company's 2021 Stock Option and Incentive Plan, or the 2021 Plan, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's initial public offering, or IPO, was declared effective. The 2021 Plan provides for the grant of incentive stock options; non-qualified stock options; stock appreciation rights; restricted stock units, or RSUs; restricted stock awards; unrestricted stock awards; cash-based awards and dividend equivalent rights to the Company's officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2021 Plan was 4,903,145. Under the evergreen provision of the 2021 Plan, the shares available for issuance under the 2021 Plan will be automatically increased each January 1st by 5% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or such lesser number of shares as may be determined by the Company's compensation, nomination and corporate governance committee. Effective January 1, 2026 the number of shares available under the 2021 Plan automatically increased by 3,277,186 shares pursuant to the evergreen provision of the 2021 Plan. As of September 30, 2026, 2,278,117 shares were available for issuance under the 2021 Plan.

2021 Employee Stock Purchase Plan

The Company's 2021 Employee Stock Purchase Plan, or the 2021 ESPP, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's IPO was declared effective. A total of 439,849 shares of the Company's common stock were initially reserved for issuance under the 2021 ESPP. The shares available for issuance under the 2021 ESPP will be automatically increased on each January 1st, through January 1, 2031, by the least of (i) 439,849 shares of the Company's common stock, (ii) 1% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or (iii) such lesser number of shares of the Company's common stock as determined by the plan administrator of the 2021 ESPP. Effective January 1, 2026 the number of shares available under the 2021 ESPP automatically increased by 439,849 shares pursuant to the evergreen provision of the 2021 ESPP. As of September 30, 2026, 2,078,644 shares were available for issuance under the 2021 ESPP.

2026 Inducement Plan

The Company's 2026 Inducement Plan, or the 2026 Plan, was approved by the Company's board of directors on March 16, 2026 and became effective on the same date. The 2026 Plan provides for the grant of non-qualified stock options, stock appreciation rights, RSUs, restricted stock awards, unrestricted stock awards, and dividend equivalent rights exclusively to individuals who were not previously employees or directors of the Company, as an inducement material to the individuals' entry into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). The number of shares reserved for issuance under the 2026 Plan was 1,500,000. As of September 30, 2026, 1,372,690 shares were available for issuance under the 2026 Plan.

Stock option activity

The Company has granted stock options to employees, non-employee directors, and others under the 2021 Plan and under the 2026 Plan.

The following summarizes stock option activity:

	Number of options	Weighted average exercise price	Weighted average remaining contractual term (years)	Aggregate intrinsic value (in thousands)
Outstanding—December 31, 2025	14,064,599	$ 7.74	7.2	$ 115,245
Granted	2,939,045	15.73		
Exercised	(1,008,520)	7.62		
Forfeited	(127,377)	9.71		
Outstanding—September 30, 2026	15,867,747	$ 9.22	7.0	$ 62,722
Vested or expected to vest—September 30, 2026	15,867,747	$ 9.22	7.0	$ 62,722
Exercisable—September 30, 2026	9,780,979	$ 8.12	6.1	$ 45,913

The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company's common stock.

Restricted stock unit activity

The Company has granted RSUs to employees under the 2021 Plan and under the 2026 Plan. Each of the RSUs represents the right to receive one share of the Company's common stock upon vesting. The RSUs will typically vest over two or four years provided the individual remains in continuous service of the Company. Accordingly, stock-based compensation expense for each RSU is recognized on a straight-line basis over the vesting term. The fair value of each RSU is based on the closing price of the Company's common stock on the date of grant.

The following summarizes RSU activity:

	Number of shares	Weighted average grant date fair value
Unvested restricted stock units as of December 31, 2025	775,765	$ 7.05
Granted	606,890	$ 15.63
Vested	(190,388)	$ 7.01
Forfeited	(20,851)	$ 10.63
Unvested restricted stock units as of September 30, 2026	1,171,416	$ 11.44

The aggregate fair value of RSUs that vested during the nine months ended September 30, 2026 and 2025 was $3.0 million and $0.5 million, respectively. The weighted average grant date fair value of RSUs that vested during the nine months ended September 30, 2026 and 2025 was $7.01 and $7.55 per share, respectively.

Stock-based compensation expense

Stock-based compensation expense is classified as follows (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Research and development	$ 3,283	$ 2,460	$ 9,932	$ 8,500
General and administrative	$ 3,040	1,904	8,310	6,056
Total stock-based compensation expense	$ 6,323	$ 4,364	$ 18,242	$ 14,556

As of September 30, 2026 total unrecognized stock-based compensation cost related to unvested stock options and restricted stock units was $43.5 million and $10.8 million, respectively. The Company expects to recognize this remaining cost over a weighted average period of 2.4 years and 2.8 years, respectively.

12. Income taxes

The following table summarizes the income tax (provision) benefit recorded (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Income tax (provision) benefit	$ (716)	$ 3,177	$ (976)	$ 1,156

For the three and nine months ended September 30, 2026, the Company recorded an income tax provision of $0.7 million and $1.0 million, respectively, which were primarily related to interest income on marketable securities in Massachusetts and current federal and state taxes on U.S. taxable income generated from collaboration revenue.

For the three months ended September 30, 2025, the income tax benefit was primarily related to the enactment of the "One Big Beautiful Bill Act," or OBBA. On July 4, 2025, H.R. 1, the OBBA, was signed into law. The modification to IRC Sec. 174 included in the OBBA allows the deduction of domestic based research and development expenses in the period in which they are incurred, which reduced the taxable income which was being generated from the $150 million upfront payment for the 2024 Novartis Agreement. In accordance with U.S. GAAP, the Company has accounted for the tax effects of changes in tax law in the period of enactment. As a result of these factors, in the third quarter of 2025, the Company reduced its provision for income taxes by $3.2 million. For the nine months ended September 30, 2025, the tax benefit of $1.2 million was primarily related to the requirement of carrying back the Research and Development credit generated in tax year 2025 to the tax liability of 2024.

The Company continues to maintain a full valuation allowance against all of its deferred tax assets. The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. The Company has considered its history of cumulative net losses incurred since inception and its lack of any commercial products. The Company has concluded that it is more likely than not that it will not realize the benefits of its deferred tax assets. The Company reevaluates the positive and negative evidence at each reporting period.

13. Net earnings (loss) per common share

Basic and diluted net earnings (loss) per share is calculated based upon the weighted-average number of shares of common stock outstanding during the period. Shares of the Company's common stock underlying pre-funded warrants are included in the calculation of the basic and diluted earnings per share.

Basic and diluted net earnings (loss) per share are as follows (in thousands except share and per share amounts):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Net income (loss)	$ 3,063	$ (27,081)	$ (84,837)	$ 7,509
Basic weighted average shares outstanding	101,793,104	82,397,753	101,058,958	82,245,324
Effect of potentially dilutive securities:				
Stock options to purchase common stock	6,301,855	—	—	649,847
Restricted stock units	520,755	—	—	47,552
Diluted weighted average shares outstanding	108,615,714	82,397,753	101,058,958	82,942,723
Basic net earnings (loss) per share	$ 0.03	$ (0.33)	$ (0.84)	$ 0.09
Diluted net earnings (loss) per share	$ 0.03	$ (0.33)	$ (0.84)	$ 0.09

The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net earnings (loss) per common share, as their effect is anti-dilutive:

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Stock options to purchase common stock	9,565,892	14,943,250	15,867,747	14,293,403
Restricted stock units	650,661	774,675	1,171,416	727,123

14. Employee retirement plans

The Company, in compliance with Swiss Law, is contracted with the AXA Leben AG, or AXA, for the provision of pension benefits in a defined benefit plan. All benefits are organized in a semi-autonomous collective foundation within the framework of the contract with AXA. Insurance benefits due are paid directly to the entitled persons by AXA in the name of and for the account of the collective foundation. The pension plan is financed by contributions of both employees and the Company. The contract between the Company and the collective foundation can be terminated by either side. In the event of a termination, the Company would have an obligation to find alternative pension arrangements for its employees. Because there is no guarantee that the employee pension arrangements would be continued under the same conditions, there is a risk, albeit remote, that a pension obligation may fall on the Company. The pension assets are pooled for all affiliated companies; the investment of assets is done by the governing bodies of the collective foundation.

The following table summarizes pension expense incurred (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Pension expense	$ 401	$ 463	$ 1,112	$ 1,306

In February 2021, the Company adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible U.S. based employees of the Company. All employees are eligible to become participants of the plan immediately upon hire. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right, but is not obligated, to make additional contributions to this plan. The Company makes safe-harbor match contributions of 100% of the first 4% of each participant's eligible compensation. In January 2024, the Company adopted a defined contribution supplemental pension plan for eligible Swiss based employees defined by Swiss Law Art.1e BVV 2, or the 1e Plan. Employees earning above a defined threshold are eligible and automatically enrolled in the 1e Plan and required contributions are determined by age and salary under Swiss Law. The Company and the employee share the costs of the 1e Plan.

The following table summarizes defined contribution expenses incurred (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Defined contribution expense	$ 271	$ 201	$ 1,004	$ 830

15. Segment data

The Company defines its segments based on the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company manages its operations as a single operating and reportable segment committed to developing a portfolio of novel and proprietary MGDs. MGDs are small molecule drugs that employ the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. As the internal reporting is based on the consolidated results, the Company has identified one operating and reportable segment. The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources. The measure of the operating segment assets is reported on the condensed consolidated balance sheet as total assets.

The accounting policies used in the segment reporting are the same as those described in the summary of significant accounting policies. (See Note 2 in the Company's annual report on Form 10-K for the year ended December 31, 2025.) The Company's CODM is the Chief Executive Officer.

The Company's reportable segment net revenues and income (loss) for the three and nine months ended September 30, 2026 and 2025 consisted of the following (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Revenue:				
Collaboration revenue	$ 54,366	$ 12,768	$ 67,544	$ 120,891
Operating expenses:				
Research and development:				
External research and development expenses:				
MRT-2359	2,633	2,176	8,534	6,363
MRT-6160	299	1,444	326	6,902
MRT-8102	5,636	7,307	21,077	10,388
Other development and discovery programs	12,405	6,288	35,113	17,216
Personnel expense	13,827	10,889	41,221	33,999
Overhead and administrative expense	10,563	8,574	31,125	24,653
General and administrative expenses:				
Personnel expense	6,947	5,696	20,016	16,854
Professional services	2,513	1,619	6,358	4,147
Facility costs and other expense	1,482	1,750	4,877	4,862
Interest and other income, net	5,718	2,717	17,242	10,846
Income tax (provision) benefit	(716)	3,177	(976)	1,156
Net income (loss)	$ 3,063	$ (27,081)	$ (84,837)	$ 7,509

Other development and discovery expenses are related to the development of our QuEEN™ discovery engine and our disclosed and undisclosed programs, including CDK2 and CCNE1. The Company's tangible assets are held in the U.S. and Switzerland with 38% and 29% of the assets held in Switzerland as of September 30, 2026 and December 31, 2025, respectively. All of the Company's collaboration revenue was generated in Switzerland during each of the three and nine months ended September 30, 2026 and 2025.

16. Subsequent events

In October 2026, the Company announced achievement of an additional milestone associated with the initiation of a second Phase 2 study initiated by its collaborator Novartis evaluating MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis. The first patient visit of this study triggered a $37.5 million milestone payment to the Company under the 2024 Novartis Agreement.

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in “Part I, Item 1A, Risk Factors” in our 2025 Annual Report and under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. You should carefully read the “Risk Factors” section of this Quarterly Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Special note regarding forward-looking statements.”

Overview

We are a biotechnology company developing a portfolio of novel and proprietary MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. MGDs work by inducing the engagement of defined surfaces identified on target proteins by an E3 ligase, such as cereblon. We have developed a proprietary and industry-leading protein degradation discovery engine, called QuEEN™ to enable our unique, and target-centric, MGD discovery and development and our rational design of MGD products. We believe our small molecule MGDs may give us significant advantages over existing therapeutic modalities, including other protein degradation approaches. We prioritize our product development on therapeutic targets backed by strong biological and genetic rationale with the goal of discovering and developing novel medicines.

Monte Rosa Therapeutics AG, a Swiss operating company, was incorporated under the laws of Switzerland in April 2018. Monte Rosa Therapeutics, Inc. was incorporated in Delaware in November 2019. In 2020, through a common control reorganization, Monte Rosa Therapeutics, Inc. acquired the net assets and shareholding of Monte Rosa Therapeutics AG. Monte Rosa Therapeutics, Inc. includes wholly owned subsidiaries Monte Rosa Therapeutics AG and Monte Rosa Therapeutics Securities Corporation. We are headquartered in Boston, Massachusetts with research operations in both Boston and Basel, Switzerland.

Recent developments

In August 2026, we dosed the first patient in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations. In September 2026, we announced achievement of a milestone associated with our collaborator Novartis initiating a global Phase 2a/b randomized, double-blind, placebo-controlled study (NCT07737743), evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391) in participants with Sjögren's disease. The first patient visit triggered a $50 million milestone payment to us under the 2024 Novartis Agreement. In October 2026, we announced positive topline results from GFORCE-1, our completed Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk, and currently expect to initiate GFORCE-2, a Phase 2b study in patients with coronary artery disease, in the first half of 2027, as well as GEMINI-1, a Phase 2 study in patients with gout, in the fourth quarter of 2026 or first quarter of 2027, and GALAXY-1, a Phase 2 study in patients with moderate to severe hidradenitis suppurativa, in the first half of 2027. In October 2026, we also announced achievement of an additional milestone associated with our collaborator Novartis initiating a second Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis. The Phase 2a/b randomized, double-blind, placebo-controlled, multicenter study (NCT07801495) will evaluate the efficacy, safety, tolerability, and dose-response relationship of MRT-6160 (DDY391). The first patient visit, which occurred subsequent to September 30, 2026, triggered a $37.5 million milestone payment to us under the 2024 Novartis Agreement.

Liquidity

To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock or warrants to purchase common stock, registered direct offerings, and through our collaboration agreements. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and, to a lesser extent, general and administrative expenditures. From our inception through the date hereof, we raised an aggregate of $1.4 billion of gross proceeds from such transactions. Since inception, we have had significant operating losses. For the nine months ended September 30, 2026, we reported a net loss of $84.8 million and for the year ended December 31, 2025, we reported a net loss of $38.6 million. As of September 30, 2026, we had an accumulated deficit of $562.1 million and had $582.6 million in cash, cash equivalents, restricted cash and marketable securities. We anticipate that our existing cash and cash equivalents and marketable securities support our cash runway into 2029.

Impact of global economic and political developments

The development of our product candidates could be disrupted and materially adversely affected in the future by global economic or political developments. In addition, economic uncertainty in global markets caused by political instability and conflict, and economic challenges caused by global pandemics or other public health events, may lead to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions. Our business, financial condition and results of operations could be materially and adversely affected by negative impacts on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen.

Components of operating results

Collaboration revenue

Collaboration revenue represents amounts earned from our collaboration and license agreements with Roche and Novartis. We expect that our revenue for the next several years will be derived primarily through our current collaboration and license agreements and any additional collaborations that we may enter into in the future.

Roche collaboration and license agreement

In October 2023, Monte Rosa AG entered into a collaboration and license agreement, or the Roche Agreement, with Roche Basel and Roche US, and together with Roche Basel, Roche. Pursuant to the Roche Agreement, the parties will

seek to identify MGDs against targets in cancer and neurological diseases selected by Roche using our proprietary drug discovery engine, where a certain number of targets selected by Roche are for a limited time subject to replacement rights owned by Roche. We will lead preclinical discovery and research activities with Roche leading late preclinical and clinical development activities.

Under the Roche Agreement, Roche will have a worldwide, exclusive license under patents and know-how controlled by us to develop and commercialize products directed to applicable targets. The license exclusivity is subject to our retained rights solely to fulfill our obligations under the arrangement.

The research collaboration activities governed by the Roche Agreement are overseen by a joint research committee.

In November 2023, we received a $50.0 million non-refundable upfront payment for the initial set of targets. Pursuant to the terms of the Roche Agreement, we expect to be entitled to receive from Roche certain variable consideration including potential preclinical milestones up to $172 million, and potential clinical, commercial and sales milestones exceeding $2 billion. We are also eligible to receive tiered royalties ranging from high-single-digit percent to low-teens percent on any products that are commercialized by Roche as a result of the collaboration.

Unless earlier terminated, the Roche Agreement will remain in effect for each product licensed under the Roche Agreement until expiration of the royalty term for the applicable product. The parties have included termination provisions in the Roche Agreement, allowing termination of the Roche Agreement in its entirety, on a country-by-country or a target-by-target basis.

2024 Novartis License Agreement

In October 2024, Monte Rosa AG and Novartis entered into a license agreement, or the 2024 Novartis Agreement, with Novartis. Pursuant to the 2024 Novartis Agreement, we granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to develop, manufacture, and commercialize VAV1 MGDs, including MRT-6160. We were responsible for completing the Phase 1 clinical study and Novartis is responsible for all subsequent development and commercial activities starting at Phase 2. In September 2026, Novartis initiated a Phase 2 clinical study of MRT-6160 (DDY391) in participants with Sjögren's disease. Development and commercial activities governed by the 2024 Novartis Agreement will be overseen by a Development Committee and a Commercialization Committee.

In December 2024, we received a $150 million non-refundable upfront payment. Pursuant to the 2024 Novartis Agreement, we are eligible to receive from Novartis up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies including (a) potential development and regulatory milestone payments, exceeding $1.5 billion if multiple indications achieve regulatory approval in multiple territories, and (b) potential sales milestone payments in connection with sales outside of the U.S., and tiered royalties on sales outside of the U.S. Novartis will be responsible for costs associated with Phase 2 clinical studies. We and Novartis also agreed to a net profit and loss sharing arrangement prior to the initiation of Phase 3 clinical trials, pursuant to which we will co-fund any global clinical development from Phase 3 onwards and will share 30% of any profits and losses associated with the manufacturing and commercialization of the licensed products in the U.S. We have defined opportunities to opt out of the net profit and loss sharing arrangement. In such case, sales in the U.S. would be entitled to the potential sales milestone payments and tiered royalties as sales outside of the U.S. Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by us and Novartis.

To date through September 30, 2026, we have earned $50 million in connection with achievement of a milestone associated with Novartis initiating a global Phase 2a/b randomized, double-blind, placebo-controlled study (NCT07737743) evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391) in participants with Sjögren’s disease. The first patient visit triggered this $50 million milestone payment to us. As there were no remaining performance obligations related to this milestone, the $50 million to be received from Novartis was recognized as collaboration revenue in the three and nine months ended September 30, 2026 and was recorded in collaboration receivable as of September 30, 2026.

In October 2026, we announced achievement of an additional milestone associated with Novartis initiating a second Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis. The Phase 2a/b randomized, double-blind, placebo-controlled, multicenter study (NCT07801495) will evaluate the efficacy, safety, tolerability, and dose-response relationship of MRT-6160 (DDY391). The first patient visit, which occurred subsequent to September 30, 2026, triggered a $37.5 million milestone payment to us.

2025 Novartis License Agreement

In September 2025, Monte Rosa AG entered into a collaboration, option, and license agreement, or the 2025 Novartis Agreement, with Novartis. Pursuant to the 2025 Novartis Agreement, we granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to degraders for one I&I program, or the First Licensed Program, and the exclusive

option to obtain exclusive, royalty-bearing, sublicensable and transferable licenses with respect to two programs from our growing preclinical immunology portfolio, or the Options, and the programs, or the Optioned I&I Programs. Such Options are individually exercisable at Novartis's discretion until a program meets criteria for investigational new drug application-filing-readiness. On a program-by-program basis, if Novartis does not exercise an Option, all rights with respect to such program are retained by us; if Novartis does exercise its Option, such program becomes a Licensed Program, or together with the First Licensed Program, the Licensed Programs. Under the 2025 Novartis Agreement, we will apply our proprietary AI/ML-enabled QuEEN™ engine for the discovery and development of degraders for the First Licensed Program and the Optioned I&I Programs. The Licensed Programs will be further developed and commercialized by Novartis, unless otherwise agreed to by the parties in accordance with the 2025 Novartis Agreement. Research activities for the Licensed Programs governed by the 2025 Novartis Agreement will be overseen by a Joint Research Committee.

In September 2025, we received a $120.0 million non-refundable upfront payment from Novartis. Pursuant to the 2025 Novartis Agreement, we are entitled to receive from Novartis payments to maintain the Options totaling up to $60.0 million, and are eligible to receive from Novartis (1) preclinical milestone payments relating to the First Licensed Program and option exercise payments related to the Options of up to $180.0 million, (2) up to $5.4 billion in clinical development, regulatory, and sales milestones relating to the First Licensed Program and the two Optioned I&I Programs, beginning upon initiation of Phase 1 studies, including (a) potential development and regulatory milestone payments up to $2.2 billion if regulatory approval is achieved for multiple indications in multiple territories and (b) potential sales milestone payments up to $3.2 billion, allocated across licensed products, and (3) tiered royalties on global net sales in the high-single to low double-digit range for the First Licensed Program and in the low double-digit range for the two Optioned I&I Programs. We will be responsible for costs related to research activities, while Novartis will be responsible for costs related to development and commercialization activities.

Research and development expenses

Our research and development expenses include:

- expenses incurred under agreements with consultants, third-party service providers that conduct research and development activities on our behalf;
- personnel costs, which include salaries, benefits, pension and stock-based compensation;
- laboratory and vendor expenses related to the execution of preclinical and clinical studies;
- laboratory supplies and materials used for internal research and development activities; and
- facilities and equipment costs.

Most of our research and development expenses have been related to the development of our QuEEN™ discovery engine and advancement of our GSPT1, NEK7, and VAV1 programs, and advancement of our disclosed and undisclosed programs including for CDK2 and CCNE1.

We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as we advance our programs and conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects, the costs of related clinical development costs or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

General and administrative expenses

Our general and administrative expenses consist primarily of personnel costs and other expenses for outside professional services, including legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and administrative consulting services, insurance costs and other operating costs. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, and the potential commercialization of our product candidates and development of commercial infrastructure.

Non-operating income and (expense)

Our non-operating income and (expense) primarily includes interest earned on our investments, including principally U.S. government-backed money-market funds and marketable securities, as well as gains and losses on transactions of our Swiss subsidiary denominated in currencies other than the U.S. Dollar.

Results of operations for the three months ended September 30, 2026 and 2025

The following sets forth our results of operations (in thousands):

	Three months ended September 30,		
	2026	2025	Dollar change
Collaboration revenue	$ 54,366	$ 12,768	$ 41,598
Operating expenses:			
Research and development	$ 45,363	$ 36,678	$ 8,685
General and administrative	10,942	9,065	1,877
Total operating expenses	56,305	45,743	10,562
Loss from operations	(1,939)	(32,975)	31,036
Other income	5,718	2,717	3,001
Net income (loss) before income taxes	3,779	(30,258)	34,037
Income tax (provision) benefit	(716)	3,177	(3,893)
Net income (loss)	$ 3,063	$ (27,081)	$ 30,144

Collaboration revenue

Collaboration revenue of $54.4 million and $12.8 million for the three months ended September 30, 2026 and 2025, respectively, represents revenue recorded under our collaboration and license agreements with Roche and Novartis. The higher collaboration revenue in the three months ended September 30, 2026 was primarily related to achievement of a $50 million milestone under the 2024 Novartis Agreement associated with the first patient visit in a Phase 2 study initiated by Novartis, evaluating MRT-6160 (DDY391) in participants with Sjögren's disease. This study is further described in the *2024 Novartis Agreement* section earlier in this Management's discussion and analysis of financial condition and results of operations.

Research and development expenses

We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates. As such, we do not track all of our internal research and development expenses on a program-by-program basis.

The following table summarizes our research and development expense (in thousands):

	Three months ended September 30,		
	2026	2025	Dollar change
External research and development expense:			
MRT-2359	$ 2,633	$ 2,176	$ 457
MRT-6160	299	1,444	(1,145)
MRT-8102	5,636	7,307	(1,671)
Other development and discovery programs	12,405	6,288	6,117
Personnel expense	13,827	10,889	2,938
Overhead and administrative expense	10,563	8,574	1,989
Total research and development expense	$ 45,363	$ 36,678	$ 8,685

As of September 30, 2026 and 2025, respectively, we had 144 and 116 employees engaged in research and development activities in our facilities in the U.S. and Switzerland.

Most of our research and development expenses were driven by the successful continued advancement in our research and development organization, including the continuation of the MRT-2359 and MRT-8102 clinical studies, the progression of our preclinical pipeline including research performed for our collaborations with Roche and Novartis, and the continued development of our QuEEN™ discovery engine, and reflect increased personnel expense and external R&D costs to for the continued advancement of our pipeline. Research and development expenses for the three months ended September 30, 2026 and 2025 included non-cash stock-based compensation expense of $3.3 million and $2.5 million, respectively.

General and administrative expenses

General and administrative expenses to support our business activities were comprised of (in thousands):

	Three months ended September 30,		
	2026	2025	Dollar change
Personnel costs	$ 6,947	$ 5,696	$ 1,251
Professional services	2,513	1,619	894
Facility costs and other expenses	1,482	1,750	(268)
Total general and administrative expenses	$ 10,942	$ 9,065	$ 1,877

As of September 30, 2026 and 2025, respectively, we had 41 and 31 employees engaged in general and administrative activities. General and administrative expenses included non-cash stock-based compensation of $3.0 million and $1.9 million for the three months ended September 30, 2026 and 2025, respectively.

Other income

Other income was comprised of (in thousands):

	Three months ended September 30,		
	2026	2025	Dollar change
Interest income	$ 5,625	$ 2,746	$ 2,879
Foreign currency exchange gain (loss)	93	(29)	122
Other income	$ 5,718	$ 2,717	$ 3,001

Other income for the three months ended September 30, 2026 and 2025 was primarily attributable to interest earned on marketable securities. The increase in interest income for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025 was principally attributable to higher average balances in marketable securities.

Income tax (provision) benefit

For the three months ended September 30, 2026, the income tax provision was primarily related to interest income on marketable securities in Massachusetts and current federal and state taxes on U.S. taxable income generated from collaboration revenue.

For the three months ended September 30, 2025, the income tax benefit was primarily related to the enactment of the "One Big Beautiful Bill Act," or OBBA. On July 4, 2025, H.R. 1, the OBBA, was signed into law. The modification to IRC Sec. 174 included in the OBBA allows the deduction of domestic based research and development expenses in the period in which they are incurred, which reduced the taxable income which was being generated from the $150 million upfront payment for the 2024 Novartis Agreement. In accordance with U.S. GAAP, we have accounted for the tax effects of changes in tax law in the period of enactment. As a result of these factors, in the third quarter of 2025, we reduced our provision for income taxes by $3.2 million.

Results of operations for the nine months ended September 30, 2026 and 2025

The following sets forth our results of operations (in thousands):

	Nine months ended September 30,		
	2026	2025	Dollar change
Collaboration revenue	$ 67,544	$ 120,891	$ (53,347)
Operating expenses:			
Research and development	137,396	99,521	37,875
General and administrative	31,251	25,863	5,388
Total operating expenses	168,647	125,384	43,263
Loss from operations	(101,103)	(4,493)	(96,610)
Other income	17,242	10,846	6,396
Net (loss) income before income taxes	$ (83,861)	$ 6,353	$ (90,214)
Income tax (provision) benefit	(976)	1,156	(2,132)
Net (loss) income	$ (84,837)	$ 7,509	$ (92,346)

Collaboration revenue

Collaboration revenue of $67.5 million and $120.9 million for the nine months ended September 30, 2026 and 2025, respectively, represents revenue recorded under our collaboration and license agreements with Roche and Novartis. Collaboration revenue in the nine months ended September 30, 2026 was primarily related to achievement of a $50 million milestone under the 2024 Novartis Agreement associated with the first patient visit in a Phase 2 study initiated by Novartis, evaluating MRT-6160 (DDY391) in participants with Sjögren's disease. This study is further described in the *2024 Novartis Agreement* section earlier in this Management's discussion and analysis of financial condition and results of operations.

Collaboration revenue in the nine months ended September 30, 2025 was primarily related to the non-refundable upfront payment from Novartis under the 2024 Novartis Agreement.

Research and development expenses

We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates. As such, we do not track all of our internal research and development expenses on a program-by-program basis.

The following table summarizes our research and development expense (in thousands):

	Nine months ended September 30,		
	2026	**2025**	**Dollar change**
External research and development expense:			
MRT-2359	$ 8,534	$ 6,363	$ 2,171
MRT-6160	326	6,902	(6,576)
MRT-8102	21,077	10,388	10,689
Other development and discovery programs	35,113	17,216	17,897
Personnel expense	41,221	33,999	7,222
Overhead and administrative expense	31,125	24,653	6,472
Total research and development expense	$ 137,396	$ 99,521	$ 37,875

As of September 30, 2026 and 2025, respectively, we had 144 and 116 employees engaged in research and development activities in our facilities in the U.S. and Switzerland.

Most of our research and development expenses were driven by the successful continued advancement in our research and development organization, including the continuation of the MRT-2359 and MRT-8102 clinical studies, the progression of our preclinical pipeline including research performed for our collaborations with Roche and Novartis, and the continued development of our QuEEN™ discovery engine, and reflect increased personnel expense, external R&D costs, and related lab expenses for the continued advancement of our pipeline. Research and development expenses for the nine months ended September 30, 2026 and 2025 included non-cash stock-based compensation expense of $9.9 million and $8.5 million, respectively.

General and administrative expenses

General and administrative expenses to support our business activities were comprised of (in thousands):

	Nine months ended September 30,		
	2026	**2025**	**Dollar change**
Personnel costs	$ 20,016	$ 16,854	$ 3,162
Professional services	6,358	4,147	2,211
Facility costs and other expenses	4,877	4,862	15
Total general and administrative expenses	$ 31,251	$ 25,863	$ 5,388

As of September 30, 2026 and 2025, respectively, we had 41 and 31 employees engaged in general and administrative activities. General and administrative expenses included non-cash stock-based compensation of $8.3 million and $6.1 million for the nine months ended September 30, 2026 and 2025, respectively.

Other income

Other income was comprised of (in thousands):

	Nine months ended September 30,		
	2026	2025	Dollar change
Interest income	$ 17,132	$ 9,253	$ 7,879
Foreign currency exchange gain	110	1,534	(1,424)
Gain on disposal of property and equipment	—	59	(59)
Other income	$ 17,242	$ 10,846	$ 6,396

Other income for the nine months ended September 30, 2026 and 2025 was primarily attributable to interest earned on marketable securities. The increase in interest income for the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025 was principally attributable to higher average balances in marketable securities. Foreign exchange gain on transactions denominated in currency other than the U.S. dollar decreased in the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, primarily due to changes in the exchange rates between the U.S. Dollar and, principally, the Swiss Franc.

Income tax (provision) benefit

For the nine months ended September 30, 2026, the income tax provision was primarily related to interest income on marketable securities in Massachusetts and current federal and state taxes on U.S. taxable income generated from collaboration revenue.

For the nine months ended September 30, 2025, the income tax benefit of $1.2 million was primarily related to the requirement of carrying back the Research and Development credit generated in tax year 2025 to the tax liability of 2024.

Liquidity and capital resources

Overview

Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock or warrants to purchase common stock, registered direct offerings, and through our collaboration agreements. As of September 30, 2026, we had $582.6 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2026, we had an accumulated deficit of $562.1 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

At-the-market offerings

On July 1, 2022, we entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $100.0 million of our common stock from time to time in “at-the-market” offerings, or the ATM Program, through July 2025 under registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the 2022 Shelf Registration Statement and subject to the limitations thereof.

On March 20, 2025, we filed a registration statement on Form S-3 (File No. 333-285942) with the SEC, which was declared effective on March 31, 2025, or the 2025 Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into the Amendment No. 1 to the Sales Agreement, or the Amendment, with Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $150.0 million of our common stock from time to time under the ATM Program, pursuant to a prospectus supplement, dated March 20, 2025, under 2025 Shelf Registration Statement, or the Original Prospectus Supplement, and subject to the limitations thereof. Under the Original Prospectus Supplement, we sold 2,955,082 shares of our common stock for aggregate gross proceeds of $25.0 million, or aggregate net proceeds of $23.9 million, pursuant to the Sales Agreement. As disclosed in a Current Report on Form 8-K filed on January 7, 2026, the Original Prospectus Supplement was terminated, effective as of January 7, 2026, and we did not issue any additional shares under the ATM Program following such termination.

On February 11, 2026, we filed a registration statement on Form S-3ASR (File No. 333-293389) with the SEC, or the 2026 Automatic Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. In connection with the ATM Program and pursuant to the 2026 Automatic Shelf Registration Statement, we filed a new prospectus supplement with the SEC on February 11, 2026, for the offer and sale of up to $100.0 million of shares of common stock from time to time through Jefferies. As of September 30, 2026, we have sold no shares pursuant to our ATM program under the new prospectus supplement.

We will pay to Jefferies cash commissions of up to 3.0% of the aggregate gross proceeds of sales of common stock under the Sales Agreement, as amended.

Underwritten public offerings

In January 2026, we entered into an underwriting agreement with Jefferies LLC, or Jefferies, TD Securities (USA) LLC, and Piper Sandler & Co. as representative of the several underwriters, related to the underwritten public offering, or the 2026 Offering, of 13,000,000 shares of common stock at a price of $24.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a price of $23.9999 per pre-funded warrant, which represents the price per share at which shares of common stock were sold in the 2026 Offering, minus $0.0001, which is the exercise price of each pre-funded warrant. The 13,000,000 shares of common stock includes the full exercise by the underwriters of their option to purchase an additional 1,875,000 shares of common stock at the public offering price. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the 2026 Offering were $345.0 million. Aggregate net proceeds from the 2026 Offering were $323.8 million after deducting the underwriter discounts, commissions, and other offering costs.

During the nine months ended September 30, 2026, 5,641,658 pre-funded warrants were exercised and, net of cashless exercises, 5,641,620 shares of common stock were issued as a result. During the nine months ended September 30, 2025, no pre-funded warrants were exercised.

Cash flows

The following table summarizes our cash flows for the periods indicated (in thousands):

	Nine months ended September 30,	
	2026	**2025**
Net cash (used in) provided by:		
Operating activities	$ (122,461)	$ 20,216
Investing activities	(294,392)	(36,767)
Financing activities	332,114	727
Net decrease in cash, cash equivalents and restricted cash	$ (84,739)	$ (15,824)

Operating activities

Net cash used in operating activities of $122.5 million during the nine months ended September 30, 2026 was attributable to our net loss of $84.8 million, changes of $42.8 million in our working capital accounts, and a decrease in deferred revenue of $17.5 million, partially offset by non-cash charges of $22.7 million, principally with respect to depreciation expense and stock-based compensation. The changes in working capital accounts included a $43.0 million increase in collaboration receivable.

Net cash provided by operating activities of $20.2 million during the nine months ended September 30, 2025, was attributable to our net income of $7.5 million; non-cash charges of $18.5 million, principally with respect to depreciation expense and stock-based compensation; and an increase in deferred revenue of $3.3 million. This was partially offset by decreases in our working capital of $9.1 million.

Investing activities

Cash used in investing activities of $294.4 million during the nine months ended September 30, 2026 was primarily attributable to purchases of marketable securities of $499.8 million and purchases of property and equipment of $8.1 million, partially offset by proceeds from the maturity of marketable securities of $213.5 million.

Cash used in investing activities of $36.8 million during the nine months ended September 30, 2025 was primarily attributable to purchases of marketable securities of $223.0 million and purchases of property and equipment of $3.9 million, partially offset by proceeds from the maturity of marketable securities of $190.2 million.

Financing activities

Cash provided by financing activities of $332.1 million for the nine months ended September 30, 2026 was primarily due to the proceeds from the 2026 Offering and to the exercise of employee stock options.

Cash provided by financing activities of $0.7 million for the nine months ended September 30, 2025 was primarily due to the proceeds from purchases from the 2021 ESPP and to the exercise of employee stock options.

Funding requirements

Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs.

Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

- the scope, progress, results and costs of researching, developing and manufacturing our current product candidates or any future product candidates, and conducting preclinical studies and clinical trials;
- the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates;
- the number and characteristics of any additional product candidates we develop or acquire;
- the cost of manufacturing our lead product candidate or any future product candidates and any products we successfully commercialize, including costs associated with building-out our manufacturing capabilities;
- our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into;
- the expenses needed to attract and retain skilled personnel;
- the costs associated with being a public company;
- the timing, receipt and amount of sales of any future approved or cleared products, if any; and
- the impact of global economic and political developments, future public health events and the corresponding responses of businesses and governments.

Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and

commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.

Critical accounting policies and significant judgments and estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our unaudited interim condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes to our critical accounting policies from those described in "Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our 2025 Annual Report.

For a complete discussion of our significant accounting policies and recent accounting pronouncements, see Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report and Note 2 to our 2025 Annual Report.

Recently issued and adopted accounting pronouncements

Refer to Note 2, "Summary of significant accounting policies," in the accompanying notes to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.

Contractual obligations and commitments

During the three months ended September 30, 2026, there have been no material changes to our contractual obligations and commitments from those described under "Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026.

Emerging growth and smaller reporting company status

In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Therefore, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies instead of the dates required for other public companies.

We will cease to be an emerging growth company on December 31, 2026, which is the last day of our fiscal year following the fifth anniversary of the date of the closing of our initial public offering, or our IPO. The loss of emerging growth company status will not impact our "non-accelerated filer" status, which also provides an exemption from the auditor attestation requirement with respect to internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002.

In addition, we are also a "smaller reporting company" as defined in Rule 12b-2 of the Exchange Act and have elected to take advantage of certain of the scaled back disclosure requirements available to smaller reporting companies, such as reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and the ability to present only the two most recent fiscal years of audited financial statements in our annual reports on Form 10-K. We will continue to qualify as a smaller reporting company if we have (i) a public float of less than $250 million or (ii) annual revenues of less than $100 million and either no public float or a public float of less than $700 million, in each case as determined as of the last business day of our most recently completed second fiscal quarter (with annual revenues measured as of our most recently completed fiscal year for which audited financial statements are available). In August 2025, the SEC staff issued Exchange Act Rules C&DI 130.05 clarifying the filer status transition for registrants that lose

their smaller reporting company status based on the revenue tests. If we lose smaller reporting company status under the revenue test, under this interpretation, we will remain a non-accelerated filer for filings due in the fiscal year immediately following the loss of smaller reporting company status, allowing us to retain the exception from the auditor attestation requirement on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. However, the interpretation specifies that we will lose eligibility for all other smaller reporting company accommodations beginning with the Form 10-Q for the first fiscal quarter of the year after losing smaller reporting company status.

Item 3. Quantitative and qualitative disclosures about market risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this Item 3.

Item 4. Controls and procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2026. The term “disclosure controls and procedures,” as defined in the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2026 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

Inherent limitations on effectiveness of controls

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

Part II – Other Information

Item 1. Legal proceedings

From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of September 30, 2026, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk factors

Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, those risks and uncertainties discussed in "Part I, Item 1A, Risk Factors" in our 2025 Annual Report, as amended and supplemented by the information in our subsequent Quarterly Reports on Form 10-Q, together with all of the other information contained in this Quarterly Report, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report. The risk factor disclosure in our 2025 Annual Report and subsequent Quarterly Reports on Form 10-Q is qualified by the information that is described in this Quarterly Report. If any of the risks described below or in our 2025 Annual Report actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.

Other than as set forth below, there have been no material changes to the risk factors set forth in our 2025 Annual Report.

We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.

Since our inception, we have focused substantially all of our efforts and financial resources on developing our proprietary QuEEN™ discovery engine, our proprietary MGD library and our initial pipeline of product candidates. To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, and our convertible preferred stock to outside investors in private equity financings, public offerings of our common stock or warrants to purchase common stock, registered direct offerings, and our collaboration agreements with Roche and Novartis. From our inception through the date hereof, we raised an aggregate of $1.4 billion of gross proceeds from such transactions. As of September 30, 2026, our cash, cash equivalents, restricted cash and marketable securities were $582.6 million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of $562.1 million as of September 30, 2026. For the nine months ended September 30, 2026, we reported a net loss of $84.8 million. For the year ended December 31, 2025, we reported a net loss of $38.6 million. Substantially all of our operating losses have resulted from costs incurred in connection with our research and initial pipeline programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders' deficit and working capital. We expect our expenses to significantly increase in connection with our ongoing activities, as we:

- conduct our clinical trials for MRT-2359, our MGD product candidate targeting GSPT1, including MODeFIRe-1, our Phase 2 study of MRT-2359 in combination with apalutamide;
- advance our Phase 2 clinical trials for MRT-8102, our NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6, including GFORCE-2, GEMINI-1, and GALAXY-1;
- continue preclinical activities for CCNE1 and for CDK2 and other currently undisclosed programs;
- prepare and submit IND applications with the U.S. Food and Drug Administration, or FDA, for other current and future product candidates;
- complete preclinical studies for current or future product candidates;
- progress MGD molecules from our initial programs through lead optimization to development candidates and multiple areas of interest and indications;
- initiate and complete clinical trials for current or future product candidates;

- expand and improve the capabilities of our QuEEN™ discovery engine;
- continue to build our proprietary library of MGDs;
- contract to manufacture our product candidates;
- advance research and development related activities to expand our product pipeline;
- seek regulatory approval for our product candidates that successfully complete clinical development;
- develop and scale up our capabilities to support our ongoing preclinical activities and future clinical trials for our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval;
- maintain, expand, and protect our intellectual property portfolio;
- hire additional staff, including clinical, scientific and management personnel; and
- secure facilities to support continued growth in our research, development and commercialization efforts.

In addition, if we obtain marketing approval for our current or future product candidates, we will incur significant expenses relating to our commercialization of such product candidates via our sales, marketing, product manufacturing and distribution efforts. Because of the numerous risks and uncertainties associated with developing pharmaceutical drugs, including in light of any economic fluctuations, we are unable to predict the extent of any future losses or when we will become profitable, if at all.

Even if we achieve profitability, we may not be able to sustain or increase our profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

Item 2. Unregistered sales of equity securities, use of proceeds and issuer purchases of equity securities

Recent sales of unregistered equity securities

None.

Issuer purchases of equity securities

None.

Item 3. Defaults upon senior securities

None.

Item 4. Mine safety disclosures

Not Applicable.

Item 5. Other information

Rule 10b5-1 Trading Plans

During the fiscal quarter ended on September 30, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit Number	Description
3.1	Fourth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on June 28, 2021).
3.2	Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on June 14, 2023).
3.3	Second Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.3 of the Registrant's Quarterly Report on Form 10-Q (File No. 001-40522) filed on May 9, 2024)
31.1*	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
104*	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Monte Rosa Therapeutics, Inc.

Date: November 5, 2026

By: /s/ Markus Warmuth

Markus Warmuth
Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Markus Warmuth, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ending September 30, 2026 of Monte Rosa Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2026

By: /s/ Markus Warmuth
Markus Warmuth
Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Monte Rosa Therapeutics, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 5, 2026

By: /s/ Markus Warmuth
Markus Warmuth
Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)